DelveInsight’s, “Protein Tyrosine Phosphatase Non Receptor Type 11 Antagonists – Pipeline Insight, 2022,” report provides comprehensive insights about 7+ companies and 8+ pipeline drugs in Protein Tyrosine Phosphatase Non Receptor Type 11 Antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Protein Tyrosine Phosphatase Non Receptor Type 11 Antagonists: Overview
Tyrosine-protein phosphatase non-receptor type 11 (PTPN11) also known as protein-tyrosine phosphatase 1D (PTP-1D), Src homology region 2 domain-containing phosphatase-2 (SHP-2), or protein-tyrosine phosphatase 2C (PTP-2C) is an enzyme that in humans is encoded by the PTPN11 gene. PTPN11 is a protein tyrosine phosphatase (PTP) Shp2. PTPN11 is a member of the protein tyrosine phosphatase (PTP) family. PTPs are known to be signaling molecules that regulate a variety of cellular processes including cell growth, differentiation, mitotic cycle, and oncogenic transformation. This PTP contains two tandem Src homology-2 domains, which function as phospho-tyrosine binding domains and mediate the interaction of this PTP with its substrates. This PTP is widely expressed in most tissues and plays a regulatory role in various cell signaling events that are important for a diversity of cell functions, such as mitogenic activation, metabolic control, transcription regulation, and cell migration. More recently, there has been renewed interest in developing inhibitors of the tyrosine phosphatase SHP2 (PTPN11) in the light of its broad role in cancer, specifically juvenile myelomonocytic leukemia, and recent studies that implicate SHP2 as a key factor in breast cancer progression.
"Protein Tyrosine Phosphatase Non Receptor Type 11 Antagonists - Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Protein Tyrosine Phosphatase Non Receptor Type 11 Antagonists pipeline landscape is provided which includes the disease overview and Protein Tyrosine Phosphatase Non Receptor Type 11 Antagonists treatment guidelines. The assessment part of the report embraces, in depth Protein Tyrosine Phosphatase Non Receptor Type 11 Antagonists commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Protein Tyrosine Phosphatase Non Receptor Type 11 Antagonists collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
The companies and academics are working to assess challenges and seek opportunities that could influence Protein Tyrosine Phosphatase Non Receptor Type 11 Antagonists R&D. The therapies under development are focused on novel approaches to treat/improve Protein Tyrosine Phosphatase Non Receptor Type 11 Antagonists.
This segment of the Protein Tyrosine Phosphatase Non Receptor Type 11 Antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Protein Tyrosine Phosphatase Non Receptor Type 11 Antagonists Emerging Drugs
RMC-4630: Revolution medicines
RMC-4630 is a potent and selective inhibitor of SHP2, a central node in the RAS signaling pathway currently being evaluated in Phase II stage of development for the treatment of Non-Small cell lung cancer. The RMC-4630 program is the focus of an exclusive global research, development and commercialization agreement with Sanofi, under which the company received a $50 million upfront payment, and Sanofi agreed to cover all development costs and certain research costs for the joint SHP2 program. Sanofi received an exclusive worldwide license for global commercialization of any approved products targeting SHP2, subject to a U.S. co-promote right for Revolution Medicines.
JAB-3068: Jacobio Pharmaceuticals
SHP2 is a ubiquitously expressed non-receptor tyrosine phosphatase that is activated upon interaction of the N-terminal SH2 domains with phosphorylated cell surface receptors (e.g., pRTKs, pPD-1, etc.) to transduce extracellular signals. SHP2 regulates survival and proliferation primarily via the RAS-ERK pathway, specifically RTK, NF1 loss, RAS, Class-III RAF-driven cancers depend on SHP2. SHP2 is also implicated in immune evasion via the PD-1 and BTLA immune checkpoint pathways. AbbVie has obtained from Jacobio Pharmaceuticals an exclusive global license, excluding greater China, to develop and commercialize JAB-3068 and JAB-3312.
Further product details are provided in the report……..
This segment of the report provides insights about the different Protein Tyrosine Phosphatase Non Receptor Type 11 Antagonists drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 7+ key companies which are developing the therapies for Protein Tyrosine Phosphatase Non Receptor Type 11 Antagonists. The companies which have their Protein Tyrosine Phosphatase Non Receptor Type 11 Antagonists drug candidates in the most advanced stage, i.e. phase II include Revolution medicines.
DelveInsight’s report covers around 8+ products under different phases of clinical development like
Protein Tyrosine Phosphatase Non Receptor Type 11 Antagonists pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Protein Tyrosine Phosphatase Non Receptor Type 11 Antagonists therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Protein Tyrosine Phosphatase Non Receptor Type 11 Antagonists drugs.
Current Treatment Scenario and Emerging Therapies:
Introduction
Executive Summary
Protein Tyrosine Phosphatase Non Receptor Type 11 Antagonists: Overview
Pipeline Therapeutics
Therapeutic Assessment
Mid Stage Products (Phase II)
RMC-4630: Revolution medicines
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
ERAS-601: Erasca
Drug profiles in the detailed report…..
Inactive Products
Protein Tyrosine Phosphatase Non Receptor Type 11 Antagonists Key Companies
Protein Tyrosine Phosphatase Non Receptor Type 11 Antagonists Key Products
Protein Tyrosine Phosphatase Non Receptor Type 11 Antagonists- Unmet Needs
Protein Tyrosine Phosphatase Non Receptor Type 11 Antagonists- Market Drivers and Barriers
Protein Tyrosine Phosphatase Non Receptor Type 11 Antagonists- Future Perspectives and Conclusion
Protein Tyrosine Phosphatase Non Receptor Type 11 Antagonists Analyst Views
Protein Tyrosine Phosphatase Non Receptor Type 11 Antagonists Key Companies
Appendix
List of Table
Table 1: Total Products for Protein Tyrosine Phosphatase Non Receptor Type 11 Antagonists
Table 2: Late Stage Products
Table 3: Mid Stage Products
Table 4: Early Stage Products
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Product Type
Table 7: Assessment by Stage and Product Type
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: Inactive Products
List of Figures
Figure 1: Total Products for Protein Tyrosine Phosphatase Non Receptor Type 11 Antagonists
Figure 2: Late Stage Products
Figure 3: Mid Stage Products
Figure 4: Early Stage Products
Figure 5: Preclinical and Discovery Stage Products
Figure 6: Assessment by Product Type
Figure 7: Assessment by Stage and Product Type
Figure 8: Assessment by Route of Administration
Figure 9: Assessment by Stage and Route of Administration
Figure 10: Assessment by Molecule Type
Figure 11: Assessment by Stage and Molecule Type
Figure 12: Inactive Products
• InnoCare Pharma
• HUYA Bioscience International
• Erasca
• REVOLUTION Medicines
• Jacobio Pharmaceuticals
• BridgeBio Pharma
• Shanghai ETERN Biopharma
• Redx Pharma
